Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katherine L. Oliver
Observed name:
Katherine Oliver
Institution:
Cellectar Biosciences (United States)
Observed institutions:
National Institutes of Health,
University of Wisconsin System,
University of Wisconsin–Madison,
University of Wisconsin Carbone Cancer Center,
National Institute of Neurological Disorders and Stroke,
Cellectar Biosciences (United States)
show all 6
OpenAlex ID:
A5103979212
Prospective study of neurological responses to treatment with macrophage‐targeted glucocerebrosidase in patients with type 3 Gaucher's disease
1997
·
Raphael Schiffmann
, Melvyn P. Heyes
, et al.
·
Annals of Neurology
·
112
Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher Disease
1997
·
Roscoe O. Brady
, Gary J. Murray
, et al.
·
PEDIATRICS
·
53
In Vitro studies of skeletal muscle membranes
1977
·
Barry W. Festoff
, Katherine L. Oliver
, et al.
·
The Journal of Membrane Biology
·
39
In vitro studies of skeletal muscle membranes
1977
·
Barry W. Festoff
, Katherine L. Oliver
, et al.
·
The Journal of Membrane Biology
·
32
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
2015
·
Sam Joseph Lubner
, Jacqueline Mullvain
, et al.
·
Cancer Investigation
·
24
Differences in catecholamine-sensitive adenylate cyclase and β-adrenergic receptor binding between fast-twitch and slow-twitch skeletal muscle membranes
1979
·
N. Bojji Reddy
, Katherine L. Oliver
, et al.
·
Life Sciences
·
23
Interaction of Human Placental Glucocerebrosidase With Hepatic Lectins
1984
·
F. Scott Furbish
, Katherine L. Oliver
, et al.
·
Elsevier eBooks
·
15
A Phase I Study of a DNA Vaccine Targeting Prostatic Acid Phosphatase in Patients with Stage D0 Prostate Cancer
2005
·
Sarah Zlotocha
, Mary Jane Staab
, et al.
·
Clinical Genitourinary Cancer
·
12
A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors
2011
·
Trevor W. Dennie
, Ronald A. Fleming
, et al.
·
Clinical Colorectal Cancer
·
8
Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) treated with CLR 131.
2021
·
Sikander Ailawadhi
, Asher Alban Akmal Chanan-Khan
, et al.
·
Journal of Clinical Oncology
·
5
Efficacy of repeated injections of CLR 131 (I-131-CLR1404) in a MES SA/Dx5 athymic nude mouse model.
2017
·
Katherine Oliver
, Jarrod Longcor
, et al.
·
Journal of Clinical Oncology
·
1
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
2016
·
Sikander Ailawadhi
, Patrick J. Stiff
, et al.
·
Blood
·
1
Iopofosine I-131 after BTK inhibitors in Waldenström macroglobulinemia: CLOVER-WaM subgroup efficacy and safety.
2026
·
Jarrod Longcor
, Sikander Ailawadhi
, et al.
·
Journal of Clinical Oncology
Efficacy of a single-dose injection of CLR 131 (1-131-CLR1404) in a Caki-2 athymic nude mouse model.
2017
·
Jarrod Longcor
, Katherine Oliver
, et al.
·
Journal of Clinical Oncology
Efficacy of a repeat dose injection of CLR 131 (I-131-CLR1404) in U87-MG tumor-bearing athymic nude mice.
2017
·
Katherine Oliver
, Jarrod Longcor
, et al.
·
Journal of Clinical Oncology
A phase 1 study of phospholipid ether [131I]-CLR1404 in patients with advanced solid tumors.
2014
·
Sam Joseph Lubner
, Jacqueline Ann Mullvain
, et al.
·
Journal of Clinical Oncology
Cell line GM-4390 deficient in lysosomalα-galactosidase activity
1991
·
Christine R. Kaneski
, Katherine L. Oliver
, et al.
·
In Vitro Cellular & Developmental Biology - Animal
Show more works
View as search
Works count:
17
Citation count:
325
H-index:
8
I10-index:
8
Year
Topic
Type
